Skip to main content
. 2016 Jul 21;18(5):410–422. doi: 10.1111/bdi.12415

Table 3.

Summary of pathway analysis results

Name P‐value q‐value Ratioa
Canonical pathways
Dopamine‐DARPP32 (Dopamine‐ and cAMP‐regulated phosphoprotein, Mr 32 kDa) feedback in cAMP signalling 4.33×10−5 2.31×10−2 47/155 (0.303)
PI3K signalling in B lymphocytes 1.21×10−4 3.07×10−2 38/122 (0.311)
Wnt/β‐catenin signalling 2.28×10−4 3.07×10−2 47/165 (0.285)
Endometrial cancer signalling 2.30×10−4 3.07×10−2 20/52 (0.385)
Protein kinase A signalling 4.18×10−4 3.27×10−2 89/368 (0.242)
Name P‐value range q‐value range No. molecules
Molecular and cellular functions
Cell‐to‐cell signalling and interaction 1.72×10−15–5.15×10−3 3.71×10−11–2.61×10−1 225
Cellular assembly and organization 1.72×10−15–6.83×10−3 3.71×10−11–3.01×10−1 520
Cell death and survival 8.83×10−8–6.27×10−3 1.00×10−4–2.87×10−1 924
Cell morphology 2.67×10−6–6.57×10−3 1.20×10−3–2.97×10−1 662
Cellular development 8.43×10−6–7.42×10−3 3.30×10−3–3.19×10−1 898
Physiological system development and function
Nervous system development and function 1.72×10−15–7.42×10−3 3.71×10−11–3.19×10−1 620
Tissue morphology 1.72×10−15–7.24×10−3 3.71×10−11–3.15×10−1 582
Behaviour 3.48×10−8–6.64×10−3 4.69×10−5–2.97×10−1 283
Embryonic development 5.97×10−7–7.24×10−3 4.37×10−4–3.15×10−1 515
Organismal development 5.97×10−7–6.64×10−3 4.37×10−4–2.97×10−1 711
Diseases and disorders
Cancer 6.66×10−11–6.57×10−3 2.06×10−7–2.97×10−1 2714
Gastrointestinal disease 6.66×10−11–4.88×10−3 2.06×10−7–2.61×10−1 2042
Organismal injury and abnormalities 6.66×10−11–7.26×10−3 2.06×10−7–3.15×10−1 2717
Hepatic system disease 5.72×10−9–2.01×10−8 1.24×10−5–2.89×10−5 1185
Hereditary disorder 5.79×10−7–6.88×10−3 4.37×10−4–3.01×10−1 187
a

The ratio indicates the number of molecules associated with a particular pathway, disease or function in the target set compared to the reference set.